Literature DB >> 15463843

Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

Tim W R Lee1, Keith G Brownlee, Steven P Conway, Miles Denton, James M Littlewood.   

Abstract

BACKGROUND: Patients were defined each successive month as either 'chronic' when more than 50% of the preceding 12 months were PA culture positive, 'intermittent' when < or =50% of the preceding 12 months were PA culture positive, 'free of PA', with no growth of PA for the previous 12 months, having previously been PA culture positive, or 'never infected', when PA had never been cultured.
METHODS: Cross-sectional analysis of 146 children attending the Leeds Regional Cystic Fibrosis Centre was performed to assess relationship between the new definition and clinical scores and investigations. The response variable was regressed on age and sex and the residuals analysed using the Kruskal-Wallis test.
RESULTS: The 'chronic' group (18% of patients) had significantly worse Shwachman-Kulczycki (SK) and Northern chest X-ray scores, and % predicted FEV(1) values than the 'free' (28%) or 'never' (20%) categories (P<0.004). The 'intermittent' group (34%) had a significantly higher SK score than the 'chronic' group (P<0.0001), and a significantly lower % predicted FEV(1) value than the 'free' or 'never' groups (P<0.0003). 'Chronic' patients were significantly associated with a positive, and 'never' patients with a negative, PA antibody result (P<0.001).
CONCLUSIONS: The validity and importance of identifying these four subgroups is demonstrated. Previous definitions may over-estimate the prevalence of chronic infection.

Entities:  

Mesh:

Year:  2003        PMID: 15463843     DOI: 10.1016/S1569-1993(02)00141-8

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  191 in total

1.  Unusual distribution of Burkholderia cepacia complex species in Danish cystic fibrosis clinics may stem from restricted transmission between patients.

Authors:  Niels Nørskov-Lauritsen; Helle Krogh Johansen; Mette G Fenger; Xiaohui C Nielsen; Tacjana Pressler; Hanne V Olesen; Niels Høiby
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

2.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

3.  Aspergillus fumigatus chronic colonization and lung function decline in cystic fibrosis may have a two-way relationship.

Authors:  M Noni; A Katelari; G Dimopoulos; S-E Doudounakis; C Tzoumaka-Bakoula; V Spoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-30       Impact factor: 3.267

4.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

5.  Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.

Authors:  Kay A Ramsay; Claire A Butler; Stuart Paynter; Robert S Ware; Timothy J Kidd; Claire E Wainwright; Scott C Bell
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

6.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

7.  Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients.

Authors:  Renan Marrichi Mauch; Claudio Lucio Rossi; Marcos Tadeu Nolasco da Silva; Talita Bianchi Aiello; José Dirceu Ribeiro; Antônio Fernando Ribeiro; Niels Høiby; Carlos Emilio Levy
Journal:  Med Microbiol Immunol       Date:  2019-01-31       Impact factor: 3.402

Review 8.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

Review 9.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

10.  Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis.

Authors:  C E Wainwright; M W France; P O'Rourke; S Anuj; T J Kidd; M D Nissen; T P Sloots; C Coulter; Z Ristovski; M Hargreaves; B R Rose; C Harbour; S C Bell; K P Fennelly
Journal:  Thorax       Date:  2009-07-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.